WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testin...(ge.Although these projections and the fa...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services
Date:12/2/2008
ge. Although these projections and the factors influencing them will likely change, we undertake no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release. Such information speaks only as of the date of this release.
Form more information, please contact:
Debra Yu, MD
Vice President Strategy
WuXi PharmaTech (Cayman) Inc.
Tel: +1-215-218-5559
Email: ir@wuxiapptec.com
Dr. Hai Mi
Executive Director of Investor Relations and Business Planning
WuXi PharmaTech (Cayman) Inc.
Tel: +86-21-5046-3726
Email: ir@wuxiapptec.com
Juliane Snowden
Vice President of Investor Relations
Burns McClellan
Tel: +1-212-213-0006
Email: jsnowden@burnsmc.com
'/>"/>
| SOURCE WuXi PharmaTech (Cayman) Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
2. WuXi PharmaTech Announces Second Quarter 2007 Results
3. WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
4. WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
5. Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech
6. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
7. WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO
8. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
9. WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs
10. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
11. WuXi PharmaTech Completes Acquisition of AppTec
Post Your Comments:
Breaking Biology Technology:YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 2New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 3Sirius Genomics Announces Change in Leadership 2BioMed Realty Announces Results of Tender Offer for its Exchangeable Notes 2BioMed Realty Announces Results of Tender Offer for its Exchangeable Notes 3
[0] YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES[0] New silicon-germanium nanowires could lead to smaller, more powerful electronic devices[0] Sirius Genomics Announces Change in Leadership[0] BioMed Realty Announces Results of Tender Offer for its Exchangeable Notes
Other Biology Technology:Albemarle Manufactures Zymes' PTS, the Lead Compound in a Breakthrough Solubilization Technology 2Albemarle Manufactures Zymes' PTS, the Lead Compound in a Breakthrough Solubilization Technology 3Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company 2Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company 3Neogen Named Supplier of Chr. Hansen Probiotics for Swine and Poultry 2
Albemarle Manufactures Zymes' PTS, the Lead Compound in a Breakthrough Solubilization TechnologyEncorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical CompanyNeogen Named Supplier of Chr. Hansen Probiotics for Swine and Poultry
Breaking Biology News(10 mins):Study reveals H1N1 unexpected weakness 2From fruit fly wings to heart failure -- why Not(ch)? 2Hebrew University, American researchers show 'trigger' to stem cell differentiation 2Experts Urge One Test to Diagnose Diabetes 48085 1Experts Urge One Test to Diagnose Diabetes 48085 2Experts Urge One Test to Diagnose Diabetes 48085 3Express Scripts to Present at William Blair Growth Stock Conference 12491 1Express Scripts to Present at William Blair Growth Stock Conference 12491 2Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference 12490 1Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference 12490 2
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |